Impact of Staphylococcus aureus on the pathogenesis of chronic cystic fibrosis lung disease.

19:36 EDT 25th October 2014 | BioPortfolio

Summary of "Impact of Staphylococcus aureus on the pathogenesis of chronic cystic fibrosis lung disease."

One of the first pathogens which can be isolated from the airways of cystic fibrosis (CF) patients is Staphylococcus aureus, which often persists in this hostile environment for many months or even years. The increase in infections due to the methicillin-resistant S. aureus (MRSA) worldwide and even more the emergence of community-acquired MRSA, which differ from nosocomial MRSA by lack of multiresistance and carriage of a phage-encoded toxin, Panton-Valentine leukocidin, attracts new attention to the epidemiology, pathogenesis, and impact of S. aureus in the background of CF. In this review, recent data and studies will be reported and discussed to give an overview of the latest research.

Affiliation

Institute of Medical Microbiology, University Hospital Münster, Domagkstraße 10, 48149 Münster, Germany.

Journal Details

This article was published in the following journal.

Name: International journal of medical microbiology : IJMM
ISSN: 1618-0607
Pages:

Links

PubMed Articles [21091 Associated PubMed Articles listed on BioPortfolio]

Oxidative modification of proteins in pediatric cystic fibrosis with bacterial infections.

Pseudomonas aeruginosa and Staphylococcus aureus cause chronic lung infection in cystic fibrosis (CF) patients, inducing chronic oxidative stress. Several markers of plasma protein oxidative damage an...

A pooling-based genomewide association study identifies genetic variants associated with Staphylococcus aureus colonization in chronic rhinosinusitis patients.

Staphylococcus aureus (S. aureus) has been implicated in the pathogenesis of chronic rhinosinusitis (CRS). However, host factors contributing to susceptibility to S. aureus colonization in CRS remain ...

Early lung disease in cystic fibrosis.

Lung disease in patients with cystic fibrosis is characterised by inflammation and recurrent and chronic infections leading to progressive loss in pulmonary function and respiratory failure. Early man...

Update on Key Emerging Challenges in Cystic Fibrosis.

Cystic fibrosis (CF) is a multisystem disease causing severe chronic sinopulmonary disease and loss of pancreatic exocrine function, which affects approximately 70,000 individuals worldwide. New thera...

Quality of life in patients with cystic fibrosis depending on the severity of the disease and method of its treatment.

Introduction: Quality of life is a measure not only of disease severity and its functional impact (physical, psychological, and social functioning) but also the efficacy of novel therapies. The aim of...

Clinical Trials [6337 Associated Clinical Trials listed on BioPortfolio]

Dissection of Staphylococcus Aureus Infection From Colonization in Cystic Fibrosis Patients

Staphylococcus aureus is not only one of the first pathogens infecting the airways of cystic fibrosis (CF) patients, but also a highly prevalent microorganism (>60% of all CF patients; Eur...

Evaluation of a Diagnostic Device for Detection of Nasal Staphylococcus Aureus

To establish the clinical test performance characteristics of sensitivity, specificity and predictive values for direct detection of nasal Staphylococcus aureus colonization against clinic...

The EPIC Observational Study

The purpose of this study is to better define risk factors preceding first isolation of Pseudomonas aeruginosa (Pa) from respiratory cultures in cystic fibrosis (CF) lung disease and to be...

Evaluation of Ciprofloxacin for Inhalation to Cystic Fibrosis Patients With P. Aeruginosa

This is a Phase 1/2a, multicenter study, designed to evaluate the pharmacokinetics, safety, and tolerability of once daily administration of 150 mg of Ciprofloxacin for Inhalation (CFI) in...

Combination Therapy With Fluoroquinolone in Staphylococcus Aureus Bacteremia

To study whether fluoroquinolone (trovafloxacin or levofloxacin), added to standard treatment, could reduce the high mortality and complication rates in Staphylococcus aureus bacteremia.

Medical and Biotech [MESH] Definitions

An autosomal recessive genetic disease of the EXOCRINE GLANDS. It is caused by mutations in the gene encoding the CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR expressed in several organs including the LUNG, the PANCREAS, the BILIARY SYSTEM, and the SWEAT GLANDS. Cystic fibrosis is characterized by epithelial secretory dysfunction associated with ductal obstruction resulting in AIRWAY OBSTRUCTION; chronic RESPIRATORY INFECTIONS; PANCREATIC INSUFFICIENCY; maldigestion; salt depletion; and HEAT PROSTRATION.

A strain of Staphylococcus aureus that is non-susceptible to the action of METHICILLIN. The mechanism of resistance usually involves modification of normal or the presence of acquired PENICILLIN BINDING PROTEINS.

A chloride channel that regulates secretion in many exocrine tissues. Abnormalities in the CFTR gene have been shown to cause cystic fibrosis. (Hum Genet 1994;93(4):364-8)

A rehabilitation therapy for removal of copious mucus secretion from the lung of patients with diseases such as CHRONIC BRONCHITIS; BRONCHIECTASIS; PULMONARY ABSCESS; or CYSTIC FIBROSIS. The patient's head is placed in a downward incline (so the TRACHEA is inferior to the affected area) for 15- to 20-minute sessions.

A strain of mice widely studied as a model for cystic fibrosis. These mice are generated from embryonic stem cells in which the CFTR (cystic fibrosis transmembrane conductance regulator) gene is inactivated by gene targeting. As a result, all mice have one copy of this altered gene in all their tissues. Mice homozygous for the disrupted gene exhibit many features common to young cystic fibrosis patients, including failure to thrive, meconium ileus, and alteration of mucous and serous glands.

Search BioPortfolio:
Loading
Advertisement

Relevant Topics

Pulmonary
Latest News Clinical Trials Research Drugs Reports Corporate
Pulmonary relating to or associated with the lungs eg Asthma, chronic bronchitis, emphysema, COPD, Cystic Fibrosis, Influenza,  Lung Cancer, Pneumonia, Pulmonary Arterial Hypertension, Sleep Disorders etc Follow and track Lung Cancer News ...

Top five promising drugs Phase I (February 2014)
Latest News Clinical Trials Research Drugs Reports Corporate
THE FIVE MOST PROMISING DRUGS ENTERING PHASE I TRIALS - February 2014 Drug Disease Company HTL-9936 Cognitive impairment Heptares Therapeutics BIOD-531 Type 2 diabetes ...

Advertisement